

**Lymphangiomyomatosis (LAM):** One \$73,491 pilot grant available focusing on proposals with strong likelihood of future federal funding, that use LAM samples, animal models or patient data, and which have the potential to favorably impact human health will be given priority.

Examples of desirable topic areas include:

- Better understanding of the molecular derangements in LAM with an aim to identify targets for future development of novel therapeutics
- Improving the existing models or creating new models to study disease pathogenesis
- Biomarker development to enable non-invasive diagnosis, better prognosticate the risk of disease progression, predict the response to treatment, or to act as end points in clinical trials. A biomarker is broadly defined as any objective modality that can measure disease activity and could include quantified biological variables (e.g., blood- or urine-based tests), novel imaging techniques, or patient-reported outcomes
- Molecular pathogenesis-guided pilot clinical trials

These grants are made possible by Team LAM Foundation Easy Breathers and The LAM Foundation.